查找临床试验
已按「甲状腺眼病」检索，对应国际通用词 thyroid eye disease
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 10:14，每 5 分钟自动同步A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
China
年龄 18 Years – 80 Years
Innovent Biologics (Suzhou) Co. Ltd.
Eye Tracking Study on Eye Movement Function and Visual Attention Patterns in Patients With Thyroid-Associated Ophthalmopathy
China
年龄 18 Years – 70 Years
Shanghai Changzheng Hospital
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
China
年龄 18 Years – 80 Years
Innovent Biologics (Suzhou) Co. Ltd.
A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy
China
年龄 18 Years – 80 Years
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis
China
年龄 不限 – 不限
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
China
年龄 18 Years – 65 Years
Shanghai Zhongshan Hospital
A Study of GensSci098 in Subjects With Graves' Disease
China
年龄 18 Years – 不限
Changchun GeneScience Pharmaceutical Co., Ltd.
Modified Orbital Decompression in the Treatment of Moderate-to-severe Grave's Ophthalmopathy
China
年龄 18 Years – 80 Years
Sun Yat-sen University
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
China
年龄 18 Years – 75 Years
Changchun GeneScience Pharmaceutical Co., Ltd.
Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.
China
年龄 18 Years – 80 Years
Peking University Third Hospital
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
China
年龄 18 Years – 80 Years
Shanghai Changzheng Hospital
Graves' Disease Remission Study: MycoMeth Combo
China
年龄 18 Years – 60 Years
The First Affiliated Hospital of Xiamen University